CN1883527A - 一种灵芝保健品及其制备方法 - Google Patents
一种灵芝保健品及其制备方法 Download PDFInfo
- Publication number
- CN1883527A CN1883527A CN 200610083790 CN200610083790A CN1883527A CN 1883527 A CN1883527 A CN 1883527A CN 200610083790 CN200610083790 CN 200610083790 CN 200610083790 A CN200610083790 A CN 200610083790A CN 1883527 A CN1883527 A CN 1883527A
- Authority
- CN
- China
- Prior art keywords
- ganoderma
- extract
- ganoderma lucidum
- dosage
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000222336 Ganoderma Species 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 230000036541 health Effects 0.000 title claims description 7
- 239000000284 extract Substances 0.000 claims abstract description 15
- 239000002245 particle Substances 0.000 claims abstract description 13
- 229930006000 Sucrose Natural products 0.000 claims abstract description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 8
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims abstract description 3
- 240000008397 Ganoderma lucidum Species 0.000 claims description 68
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims description 68
- 238000012360 testing method Methods 0.000 claims description 52
- 239000008187 granular material Substances 0.000 claims description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- 238000007689 inspection Methods 0.000 claims description 14
- 235000020710 ginseng extract Nutrition 0.000 claims description 13
- 229930003270 Vitamin B Natural products 0.000 claims description 12
- 235000019156 vitamin B Nutrition 0.000 claims description 12
- 239000011720 vitamin B Substances 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 239000004615 ingredient Substances 0.000 claims description 10
- 239000007779 soft material Substances 0.000 claims description 9
- 241000208340 Araliaceae Species 0.000 claims description 8
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 8
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 8
- 235000008434 ginseng Nutrition 0.000 claims description 8
- 229920001353 Dextrin Polymers 0.000 claims description 7
- 239000004375 Dextrin Substances 0.000 claims description 7
- 235000019425 dextrin Nutrition 0.000 claims description 7
- 239000012567 medical material Substances 0.000 claims description 7
- 239000005720 sucrose Substances 0.000 claims description 7
- 239000006286 aqueous extract Substances 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 230000003749 cleanliness Effects 0.000 claims description 3
- 239000000428 dust Substances 0.000 claims description 3
- 239000010419 fine particle Substances 0.000 claims description 3
- 238000011068 loading method Methods 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 230000036039 immunity Effects 0.000 abstract description 9
- 238000000034 method Methods 0.000 abstract description 7
- 230000008569 process Effects 0.000 abstract description 4
- 235000013402 health food Nutrition 0.000 abstract description 3
- 230000002708 enhancing effect Effects 0.000 abstract description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 abstract 1
- 229920002472 Starch Polymers 0.000 abstract 1
- 229930003451 Vitamin B1 Natural products 0.000 abstract 1
- 229930003471 Vitamin B2 Natural products 0.000 abstract 1
- 238000011010 flushing procedure Methods 0.000 abstract 1
- 238000004806 packaging method and process Methods 0.000 abstract 1
- 229960002477 riboflavin Drugs 0.000 abstract 1
- 235000019698 starch Nutrition 0.000 abstract 1
- 239000008107 starch Substances 0.000 abstract 1
- 230000001954 sterilising effect Effects 0.000 abstract 1
- 229960004793 sucrose Drugs 0.000 abstract 1
- 229960003495 thiamine Drugs 0.000 abstract 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 abstract 1
- 235000010374 vitamin B1 Nutrition 0.000 abstract 1
- 239000011691 vitamin B1 Substances 0.000 abstract 1
- 235000019164 vitamin B2 Nutrition 0.000 abstract 1
- 239000011716 vitamin B2 Substances 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 61
- 230000037396 body weight Effects 0.000 description 43
- 241000699670 Mus sp. Species 0.000 description 41
- 230000007958 sleep Effects 0.000 description 31
- 239000013642 negative control Substances 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 21
- 210000002784 stomach Anatomy 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 235000013305 food Nutrition 0.000 description 13
- 241000700159 Rattus Species 0.000 description 12
- 239000013641 positive control Substances 0.000 description 12
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 11
- 229960002275 pentobarbital sodium Drugs 0.000 description 11
- 238000010171 animal model Methods 0.000 description 10
- 230000008595 infiltration Effects 0.000 description 10
- 238000001764 infiltration Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 231100000915 pathological change Toxicity 0.000 description 9
- 230000036285 pathological change Effects 0.000 description 9
- 230000002269 spontaneous effect Effects 0.000 description 9
- 239000012153 distilled water Substances 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 231100000252 nontoxic Toxicity 0.000 description 7
- 230000003000 nontoxic effect Effects 0.000 description 7
- 230000007850 degeneration Effects 0.000 description 6
- 210000000981 epithelium Anatomy 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 5
- 229960000796 barbital sodium Drugs 0.000 description 5
- FTOAOBMCPZCFFF-UHFFFAOYSA-N barbitone sodium Natural products CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 229960004397 cyclophosphamide Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- RGHFKWPGWBFQLN-UHFFFAOYSA-M sodium;5,5-diethylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCC1(CC)C([O-])=NC(=O)NC1=O RGHFKWPGWBFQLN-UHFFFAOYSA-M 0.000 description 5
- 210000005239 tubule Anatomy 0.000 description 5
- 230000008859 change Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 230000000242 pagocytic effect Effects 0.000 description 4
- 238000012449 Kunming mouse Methods 0.000 description 3
- 206010067482 No adverse event Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 241000607142 Salmonella Species 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000000517 effect on sleep Effects 0.000 description 3
- 239000007952 growth promoter Substances 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000028527 righting reflex Effects 0.000 description 3
- 230000000920 spermatogeneic effect Effects 0.000 description 3
- 102100027211 Albumin Human genes 0.000 description 2
- 206010003084 Areflexia Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000005374 Poisoning Diseases 0.000 description 2
- 206010050294 Spleen congestion Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000002547 anomalous effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical group CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 230000007674 genetic toxicity Effects 0.000 description 2
- 231100000025 genetic toxicology Toxicity 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 239000003228 hemolysin Substances 0.000 description 2
- 230000000147 hypnotic effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000004876 tela submucosa Anatomy 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- BUCXEFZXWKUCCY-UHFFFAOYSA-N 4-methyl-3-(2-phenylethyl)-1,2,4-oxadiazol-5-one Chemical compound O1C(=O)N(C)C(CCC=2C=CC=CC=2)=N1 BUCXEFZXWKUCCY-UHFFFAOYSA-N 0.000 description 1
- CFRFHWQYWJMEJN-UHFFFAOYSA-N 9h-fluoren-2-amine Chemical compound C1=CC=C2C3=CC=C(N)C=C3CC2=C1 CFRFHWQYWJMEJN-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010063827 Extramedullary haemopoiesis Diseases 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 208000031816 Pathologic Dilatation Diseases 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010050208 Teratospermia Diseases 0.000 description 1
- 208000002312 Teratozoospermia Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 231100000644 Toxic injury Toxicity 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000005206 intestinal lamina propria Anatomy 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000029052 metamorphosis Effects 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 230000021332 multicellular organism growth Effects 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000002229 photoelectron microspectroscopy Methods 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000007015 preclinical effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000004620 sleep latency Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
动物品系 | 性别 | 数量(只) | 剂量(g/kg.bw) | 死亡动物数(只) | LD50(g/kg.bw) | 结论 |
昆明种小鼠 | 雄 | 10 | 10 | 0 | >10 | 实际无毒 |
雌 | 10 | 10 | 0 | >10 | 实际无毒 | |
SD大鼠 | 雄 | 10 | 10 | 0 | >10 | 实际无毒 |
雌 | 10 | 10 | 0 | >10 | 实际无毒 |
化合物 | 剂量(μg/皿) | S9 | 每皿回变菌落数(个/皿, X±S) | |||
TA97 | TA98 | TA100 | T102 | |||
碧生源牌灵芝颗粒自发对照阳性对照 | 84020010005000 | ------- | 112.7±10.1118.3±10.4132.0±11.1134.7±10.6157.0±12.8105.7±16.31420.0±80.0 | 38.3±4.541.0±4.444.0±6.046.0±7.046.0±5.337.3±4.51890.0±98.5 | 170.0±13.1177.0±9.6187.3±12.5194.7±13.3205.7±11.6161.0±15.51363.3±92.9 | 292.0±10.1302.3±15.7302.3±11.4312.3±18.9324.0±14.9283.3±12.51503.3±107.9 |
碧生源牌灵芝颗粒自发对照阳性对照 | 84020010005000 | +++++++ | 130.7±17.0141.7±12.0128.7±20.4143.7±10.6151.3±13.3125.7±11.01536.7±102.1 | 39.0±4.642.0±7.038.0±5.343.7±4.044.0±4.636.3±4.21836.7±94.5 | 174.3±12.5181.0±16.8197.0±13.7207.7±14.8202.3±14.6166.7±16.81360.0±90.0 | 287.3±12.1286.7±20.2297.7±12.2313.7±16.0320.3±16.3278.3±15.5920.0±80.0 |
化合物 | 剂量(μg/皿) | S9 | 每皿回变菌落数(个/皿, X±S) | |||
TA97 | TA98 | TA100 | TA102 | |||
碧生源脾灵芝颗粒自发对照阳性对照 | 84020010005000 | ------- | 126.0±9.6135.7±16.0143.0±14.5138.3±13.6156.7±13.0113.0±9.81500.0±111.4 | 38.7±4.742.0±3.640.3±6.538.3±4.944.3±5.136.0±3.61846.7±107.9 | 167.3±13.3177.3±15.4186.3±13.5197.0±12.3203.0±16.5156.7±14.01343.3±89.0 | 285.0±8.0290.7±18.1301.3±18.3300.0±19.1313.7±13.5272.7±12.21500.0±81.9 |
碧生源牌灵芝颗粒自发对照阳性对照 | 84020010005000 | +++++++ | 129.7±12.5135.3±13.3135.7±9.3148.3±17.2161.0±15.5121.0±14.51473.3±120.9 | 41.7±3.537.7±5.040.0±4.643.3±4.945.7±4.738.0±6.11843.3±92.9 | 174.7±9.1182.0±10.5190.7±13.0205.3±11.2217.0±19.2167.7±15.91296.7±116.8 | 285.0±14.8296.3±13.1309.7±13.4318.0±17.1329.7±17.8279.3±11.7933.3±96.1 |
性别 | 剂量(g/kg·bw) | 动物数(只) | 观察细胞数(个) | 微核细胞数(个) | 微核率(‰) |
雄 | 02.55.88.3环磷酰胺 | 55555 | 1000×51000×51000×51000×51000×5 | 13111214121 | 2.6±2.072.2±1.642.4±1.142.8±2.1724.2±5.07* |
雌 | 02.55.88.3环磷酰胺 | 55555 | 1000×51000×51000×51000×51000×5 | 1391314122 | 2.6±0.891.8±1.922.6±1.522.8±0.4524.4±6.54* |
组别 | 剂量(g/kg.bw) | 动物数(只) | 观察精子数(个) | 畸形精子数(个) | 精子畸形率(%) |
阴性对照受试物环磷酰胺 | 02.55.88.30.04 | 55555 | 1000×51000×51000×51000×51000×5 | 64707675326 | 1.28±0.411.40±0.161.52±0.521.50±0.606.52±0.59* |
性别 | 剂量(g/kg·bw) | 动物数(只) | 始重(g) | 第1周(g) | 第2周(g) | 第3周(g) | 第4周(g) |
雄 | 02.55.88.3 | 10101010 | 81.9±7.682.3±4.883.5±5.080.4±5.9 | 113.5±11.510.8±7.6115.5±9.0111.2±8.3 | 145.2±18.5145.5±11.3148.8±16.8143.9±10.2 | 176.6±26.1176.5±17.6180.2±21.2178.2±15.4 | 208.4±31.6210.5±20.4211.1±25.3211.6±18.9 |
雌 | 02.55.88.3 | 10101010 | 82.4±6.079.8±4.680.1±5.982.4±4.4 | 106.9±7.7105.2±5.8102.9±6.9104.8±4.8 | 129.6±8.3128.0±8.9123.5±8.4127.6±5.2 | 154.4±12.9152.6±13.9147.1±10.5152.5±7.2 | 178.6±15.4176.7±17.5171.0±12.9175.5±8.8 |
性别 | 剂量(g/kg·bw) | 周次 | 动物数(只) | 体重增重(g) | 摄食量(g) | 食物利用率(%) |
雄 | 0 | 1234总 | 1010101010 | 31.6±8.331.7±8.631.4±8.831.8±7.0126.5±27.9 | 84.2±10.6102.6±15.5120.6±19.8139.3±22.0446.7±65.7 | 36.1±6.330.4±4.425.8±3.922.7±2.428.2±2.3 |
2.5 | 1234总 | 1010101010 | 28.5±4.634.7±5.631.0±7.934.0±4.7128.2±17.8 | 80.3±7.3102.7±9.3118.2±14.3139.5±13.6439.7±41.4 | 35.9±3.533.6±2.925.9±3.624.4±2.129.1±1.6 | |
5.8 | 1234总 | 1010101010 | 32.0±7.333.3±8.631.4±7.230.9±5.3127.6±24.6 | 84.1±8.9103.7±14.2120.7±15.3137.8±16.9449.3±52.5 | 37.7±5.131.7±4.425.8±3.822.4±2.028.5±2.5 | |
8.3 | 1234总 | 1010101010 | 30.8±5.833.3±6.533.7±7.033.4±6.2131.2±19.9 | 80.9±7.3101.3±8.6120.8±12.2139.8±13.6442.8±38.3 | 37.9±4.132.7±4.427.7±3.523.9±3.329.4±2.3 | |
雌 | 0 | 1234总 | 1010101010 | 24.5±3.122.7±4.924.8±5.624.2±4.996.2±14.4 | 81.5±6.194.4±7.2111.2±11.4125.8±11.8412.9±32.3 | 29.8±2.323.8±4.122.1±3.119.1±2.823.2±2.4 |
2.5 | 1234总 | 1010101010 | 25.4±5.722.8±4.424.0±5.524.7±5.796.9±18.4 | 80.9±7.193.6±7.9109.1±11.4124.9±14.0408.5±37.9 | 31.2±5.024.1±3.121.7±3.219.6±2.823.6±2.9 | |
5.8 | 1234总 | 1010101010 | 22.8±4.820.6±4.223.6±3.723.9±5.090.9±11.6 | 78.1±6.589.3±7.0104.9±7.3120.9±10.2391.5±31.1 | 28.9±4.322.9±3.622.2±2.419.6±3.022.9±1.8 | |
8.3 | 1234总 | 1010101010 | 22.4±5.222.8±3.324.9±4.123.0±3.593.1±8.9 | 78.9±5.693.3±4.5110.0±6.4123.0±7.1405.2±19.2 | 28.4±4.724.2±2.622.5±2.618.7±1.923.0±1.3 |
性别 | 剂量(g/kg.bw) | 动物数(只) | 肝脏 | 脾脏 | 肾脏 | 睪丸 |
雄 | 02.55.88.3 | 10101010 | 31.8±3.5233.2±3.5532.2±3.5231.7±3.13 | 4.80±0.675.03±0.615.07±0.964.75±1.00 | 8.23±1.138.23±0.928.28±1.088.74±1.26 | 11.9±0.7811.5±1.0511.8±0.8111.1±0.88 |
雌 | 02.55.88.3 | 10101010 | 31.7±2.2533.4±3.8133.8±2.8432.8±2.79 | 5.16±1.565.37±1.145.07±1.054.79±1.02 | 7.95±1.038.49±0.767.83±1.038.21±0.95 | ---- |
性别 | 剂量(g/kg.bw) | 动物数(只) | RBC(1012/L) | Hb(g/L) | WBC(×109/L) | DC(%) | |
GR | LY | ||||||
雄 | 02.55.88.3 | 10101010 | 8.0±0.77.8±0.87.2±0.67.8±0.9 | 154.8±8.3i42.6±14.0149.1±18.8140.7±10.9 | 9.0±1.89.7±1.510.4±2.110.1±2.6 | 20.5±2.918.8±4.617.2±3.817.1±4.5 | 78.6±2.880.1±5.778.9±4.179.5±4.9 |
雌 | 02.55.88.3 | 10101010 | 8.4±1.08.1±0.48.3±0.77.9±0.8 | 155.1±8.5155.3±9.9160.4±12.3156.2±18.4 | 9.0±1.69.5±2.010.5±1.29.5±2.7 | 18.2±5.816.8±6.117.6±6.816.8±4.0 | 77.3±6.579.6±7.578.5±7.880.3±5.5 |
性别 | 剂量(g/kg.bw) | ALT(U/L) | AST(U/L) | TP(g/L) | ALB(g/L) | BUN(mmol/L) | CR(μmol/L) | GLU(mmol/L) | CHO(mmol/L) | TG(mmol/L) |
雄 | 02.55.88.3 | 42.4±8.536.8±5.934.8±6.446.6±10.7 | 211.5±33.4209.3±33.3185.1±14.3214.0±29.3 | 71.8±5.474.9±4.475.3±4.575.5±4.6 | 30.9±2.430.9±2.330.3±3.230.8±1.4 | 7.2±1.68.4±1.58.2±1.37.8±1.0 | 61.6±4.460.1±5.463.3±6.660.3±6.0 | 4.09±1.043.39±0.833.57±0.923.66±0.97 | 1.76±0.271.47±0.22*1.49±0.20*1.46±0.15* | 1.43±0.671.53±0.691.50±0.511.39±0.30 |
雌 | 02.55.88.3 | 30.7±7.037.4±10.235.8±10.636.3±7.7 | 189.9±24.2185.3±18.9184.0±15.9177.4±23.7 | 73.9±3.474.0±2.475.9±4.475.5±3.6 | 32.1±2.331.7±3.532.1±2.431.2±1.8 | 9.0±1.28.3±1.28.2±1.29.3±1.5 | 63.9±8.160.8±7.363.0±5.661.7±6.4 | 4.09±0.843.70±0.624.12±1.053.76±0.28 | 1.87±0.171.78±0.181.78±0.231.98±0.23 | 1.49±0.511.15±0.361.26±0.451.50±0.57 |
病理改变(例) | 阴性对照组(N=20) | 样品高剂量组(N=20) |
被膜的改变肝小叶散在点状坏死肝小叶出血肝小叶水样变肝小叶炎症细胞浸润肝轴管区炎症细胞浸润 | 000000 | 000000 |
病理改变(例) | 阴性对照组(N=20) | 样品高剂量组(N=20) |
红髓扩张白髓萎缩髓外造血灶炎细胞浸润色素沉着其它 | 110000 | 2220000 |
病理改变(例) | 阴性对照组(N=20) | 样品高剂量组(N=20) |
被膜改变肾小球细胞变性、炎细胞浸润肾小管近曲管、近直管变性肾小管近曲管、近直管坏死肾小管远曲管、远直管变性肾小管远曲管、远直管坏死肾间质局灶炎细胞浸润肾小管局灶细胞变性个别肾小管扩张 | 000000101 | 000000000 |
病理改变(例) | 阴性对照组(N=10) | 样品高剂量组(N=10) |
各级卵泡数目异常各级卵泡细胞变性各级卵泡细胞坏死炎细胞浸润 | 0000 | 0000 |
病理改变(例) | 阴性对照组(N=10) | 样品高剂量组(N=10) |
生精上皮细胞减少生精上皮细胞变性生精上皮细胞坏死多核巨细胞间质出血间质水肿 | 000000 | 000000 |
病理改变(例) | 阴性对照组(N=20) | 样品高剂量组(N=20) |
粘膜上皮变性、坏死粘膜上皮肠化固有层炎细胞浸润粘膜下层充血水肿肌层及外膜炎细胞浸润 | 00000 | 00000 |
病理改变(例) | 阴性对照组(N=20) | 样品高剂量组(N=20) |
粘膜上皮变性、坏死绒毛轴心炎细胞浸润粘膜下层充血水肿肌层及外膜炎细胞浸润 | 0000 | 0000 |
剂量(g/kg.BW) | 戊巴比妥钠剂量(mg/kg.BW) | 动物数(只) | 入睡动物数(只) | 睡眠发生率(%) | P值* |
00.831.672.50 | 28282828 | 15151515 | 2379 | 13.3320.0046.6760.00 | >0.05<0.05<0.01 |
剂量(g/kg.BW) | 戊巴比妥钠剂量(mg/kg.BW) | 动物数(只) | 睡眠时间(分)( X±S) | P值* |
00.831.672.50 | 55555555 | 13131313 | 48.35±9.6046.70±11.7340.54±11.5147.26±11.12 | >0.05>0.05>0.05 |
剂量(g/kg.BW) | 巴比妥钠剂量(mg/kg.BW) | 动物数(只) | 睡眠潜伏时间(分)( X±S) | P值* |
00.831.672.50 | 240240240240 | 13131313 | 32.48±7.7727.08±3.0624.58±5.8824.07±4.49 | <0.05<0.01<0.01 |
剂量(g/kg.BW) | 动物数(只) | 初始体重(g) | 中期体重(g) | 结束体重(g) |
00.831.672.50 | 13131313 | 20.69±0.4820.85±0.3820.69±0.4820.69±0.48 | 27.46±2.6326.69±1.7026.23±1.6427.31±2.21 | 29.54±3.1529.00±2.7428.69±2.7830.54±3.10 |
剂量(g/kg.BW) | 动物数(只) | 初始体重(g) | 中期体重(g) | 结束体重(g) |
00.831.672.50 | 15151515 | 18.73±0.8018.73±0.8018.73±0.8018.67±0.72 | 24.67±1.8026.87±1.9224.80±1.5226.13±2.03 | 26.73±2.7929.67±3.2427.73±2.5829.33±3.58 |
剂量(g/kg.BW) | 动物数(只) | 初始体重(g) | 中期体重(g) | 结束体重(g) |
00.831.672.50 | 13131313 | 22.08±0.2722.08±0.2721.92±0.2721.92±0.27 | 27.31±1.8427.23±2.3526.62±1.7627.38±2.50 | 30.23±2.9430.31±2.5931.08±2.5030.92±3.30 |
剂量(g/kg.bw) | 动物数(只) | 初始体重(g)( X±S) | 中期体重(g)( X±S) | 结束体重(g)( X±S) | 增长值(g)( X±S) |
对照组0.420.831.67 | 11111111 | 19.85±0.6719.80±0.6919.74±0.7519.99±0.92 | 21.16±1.0821.04±1.0720.95±1.1421.02±1.23 | 22.71±0.9622.55±0.9022.59±1.1022.74±1.31 | 2.85±0.772.75±0.902.85±0.662.75±0.65 |
剂量(g/kg.bw) | 动物数(只) | 初始体重(g)( X±S) | 中期体重(g)( X±S) | 结束体重(g)( X±S) | 增重(g)( X±S) |
对照组0.420.831.67 | 10111111 | 19.79±0.7419.96±0.6819.53±0.9920.00±1.04 | 20.85±1.0920.91±0.9821.28±1.0721.34±0.94 | 22.86±0.8622.95±1.0822.48±0.8722.75±1.01 | 3.07±0.812.98±0.802.94±0.612.75±0.77 |
剂量(g/kg.bw) | 动物数(只) | 初始体重(g)( X±S) | 中期体重(g)( X±S) | 结束体重(g)( X±S) | 增重(g)( X±S) |
对照组0.420.831.67 | 11111110 | 19.59±0.7019.52±0.7319.97±0.8019.68±0.75 | 21.27±0.9220.85±0.9020.85±1.0720.62±1.21 | 22.47±0.6922.31±0.8222.85±0.6222.67±1.06 | 2.88±1.082.79±0.862.87±0.832.99±1.08 |
剂量(g/kg.bw) | 动物数(只) | 初始体重(g)( X±S) | 中期体重(g)( X±S) | 结束体重(g)( X±S) | 增重(g)( X±S) |
对照组0.420.831.67 | 10111010 | 19.72±0.6719.79±0.6419.63±0.7719.97±0.67 | 21.55±0.8921.85±0.9821.56±0.9721.87±0.81 | 22.57±0.8422.55±0.7822.31±0.8722.82±0.86 | 2.85±0.702.75±0.792.68±0.812.85±0.78 |
剂量(g/kg.bw) | 动物数(只) | 脾脏/体重比值(mg/10g)( X±S) | 胸腺/体重比(mg/10g)( X±S) |
对照组0.420.831.67 | 11111111 | 41.03±3.1341.70±5.0541.39±4.7540.56±3.77 | 16.38±1.9816.11±2.3515.98±1.8616.37±1.34 |
剂量(g/kg.bw) | 动物数(只) | 足跖肿胀度(mm)( X±S) |
对照组0.420.831.67 | 11111111 | 0.20±0.070.24±0.090.24±0.060.30±0.08* |
剂量(g/kg.bw) | 动物数(只) | 光密度差值( X±S) |
对照组0.420.831.67 | 10111111 | 0.503±0.0380.556±0.0610.570±0.075*0.638±0.060** |
剂量(g/kg.bw) | 动物数(只) | 抗体积数( X±S) |
对照组0.420.831.67 | 11111111 | 174.91±11.70179.00±8.25193.00±13.94180.82±11.94** |
剂量(g/kg.bw) | 动物数(只) | 抗体生成细胞数/106(脾细胞)( X±S) |
对照组0.420.831.67 | 11111111 | 132.27±57.68147.27±55.51246.82±75.11**213.64±45.67** |
剂量(g/kg.bw) | 动物数(只) | 吞噬百分率(%)( X±S) | 吞噬指数( X±S) |
对照组0.420.831.67 | 10111111 | 29.62±4.1728.00±4.6929.36±6.2628.25±4.55 | 0.91±0.140.90±0.171.01±0.210.89±0.13 |
剂量(g/kg.bw) | 动物数(只) | 吞噬指数a( X±S) |
对照组0.420.831.67 | 10111010 | 5.20±0.435.31±0.625.30±0.406.00±0.64** |
剂量(g/kg.bw) | 动物数(只) | NK细胞活性率(%)( X±S) |
对照组0.420.831.67 | 11111111 | 20.48±5.9620.49±4.6519.28±4.9021.37±5.14 |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB200610083790XA CN100404038C (zh) | 2006-06-06 | 2006-06-06 | 一种灵芝保健品及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB200610083790XA CN100404038C (zh) | 2006-06-06 | 2006-06-06 | 一种灵芝保健品及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1883527A true CN1883527A (zh) | 2006-12-27 |
CN100404038C CN100404038C (zh) | 2008-07-23 |
Family
ID=37581909
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB200610083790XA Active CN100404038C (zh) | 2006-06-06 | 2006-06-06 | 一种灵芝保健品及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100404038C (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101828703A (zh) * | 2010-03-26 | 2010-09-15 | 武斌 | 一种增强机体免疫力并能改善睡眠质量的产品及制备方法 |
CN102488212A (zh) * | 2011-12-29 | 2012-06-13 | 山东省医药工业研究所 | 一种用于改善睡眠的保健食品及其制备方法 |
CN105685306A (zh) * | 2015-12-29 | 2016-06-22 | 广州同康药业有限公司 | 一种具有免疫调节功能的茶及其制备方法 |
CN106616967A (zh) * | 2016-09-12 | 2017-05-10 | 金龙哲 | 一种灵芝胶囊及其制备方法 |
CN113974568A (zh) * | 2021-11-09 | 2022-01-28 | 重庆火后草科技有限公司 | 基于斜率去干扰的睡眠过程的代谢率的计算方法 |
CN115300599A (zh) * | 2022-09-06 | 2022-11-08 | 北京澳特舒尔保健品开发有限公司 | 含灵芝孢子粉枸杞茯苓的护肝组合物的制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1060031C (zh) * | 1994-05-28 | 2001-01-03 | 徐士杰 | 灵芝保健饮料及其制备方法 |
CN100356929C (zh) * | 2003-08-07 | 2007-12-26 | 李湛明 | 一种辅助治疗“正气虚弱”证的药物组合物及其质量控制方法 |
-
2006
- 2006-06-06 CN CNB200610083790XA patent/CN100404038C/zh active Active
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101828703A (zh) * | 2010-03-26 | 2010-09-15 | 武斌 | 一种增强机体免疫力并能改善睡眠质量的产品及制备方法 |
CN102488212A (zh) * | 2011-12-29 | 2012-06-13 | 山东省医药工业研究所 | 一种用于改善睡眠的保健食品及其制备方法 |
CN105685306A (zh) * | 2015-12-29 | 2016-06-22 | 广州同康药业有限公司 | 一种具有免疫调节功能的茶及其制备方法 |
CN106616967A (zh) * | 2016-09-12 | 2017-05-10 | 金龙哲 | 一种灵芝胶囊及其制备方法 |
CN113974568A (zh) * | 2021-11-09 | 2022-01-28 | 重庆火后草科技有限公司 | 基于斜率去干扰的睡眠过程的代谢率的计算方法 |
CN113974568B (zh) * | 2021-11-09 | 2024-03-26 | 重庆火后草科技有限公司 | 基于斜率去干扰的睡眠过程的代谢率的计算方法 |
CN115300599A (zh) * | 2022-09-06 | 2022-11-08 | 北京澳特舒尔保健品开发有限公司 | 含灵芝孢子粉枸杞茯苓的护肝组合物的制备方法 |
CN115300599B (zh) * | 2022-09-06 | 2024-01-30 | 北京澳特舒尔保健品开发有限公司 | 含灵芝孢子粉枸杞茯苓的护肝组合物的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN100404038C (zh) | 2008-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1887101A (zh) | 一种减肥茶及其制备方法 | |
CN1195269A (zh) | 脂质代谢改善剂 | |
CN1468106A (zh) | 糖类吸收抑制剂及其制备方法 | |
CN1895073A (zh) | 一种无公害中华鳖配合饲料 | |
CN1883527A (zh) | 一种灵芝保健品及其制备方法 | |
CN103621821A (zh) | 一种缓释多元复合鲫鱼饲料及其制备方法 | |
CN1382055A (zh) | 治疗剂 | |
CN1706280A (zh) | 一种能增强免疫力的保健食品及其制备方法 | |
CN1032951C (zh) | 龟和鳖的组合物及其制备方法 | |
CN1927006A (zh) | 一种营养酵母食品及其制备方法 | |
CN1256124C (zh) | 一种补血药物组合物及其制备方法 | |
CN1376397A (zh) | 灵芝茶及其制作方法 | |
CN110074274A (zh) | 一种生长猪饲料及其制备方法 | |
CN1240297C (zh) | 肽奶及其制备工艺 | |
CN1231255C (zh) | 以南瓜为主要原料制备的治疗便秘的胶囊配方及配制方法 | |
CN1102061C (zh) | 红豆杉甘露茶 | |
CN1686405A (zh) | 一种小儿肠胃康泡腾片及其制备方法 | |
CN1166402C (zh) | 一种具有保健作用的中药组合物 | |
CN1257736C (zh) | 一种预防化学性肝损伤的解酒护肝药物组合物及制备方法 | |
CN1600147A (zh) | 一种糖肽复合物免疫强化饲料添加剂及其制备方法和用途 | |
CN1709425A (zh) | 一种抗疲劳、耐缺氧的保健品 | |
CN1113716A (zh) | 节旋藻保健食品组合物及其制法 | |
CN1568794A (zh) | 一种保健食品及其制备方法以及烘烤装置 | |
CN1251760C (zh) | 一种木瓜素含片及其生产方法 | |
CN1256123C (zh) | 黑豆浓缩丸及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: BEIJING OUT SHURE HEALTH CARE PRODUCTS CO., LTD. Free format text: FORMER OWNER: ZHAO YIHONG Effective date: 20091113 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20091113 Address after: Beijing City, Fangshan District Doudian Town Industrial District No. 1 Qiushi Patentee after: Beijing Aote Shuer Health Product Development Co., Ltd. Address before: Shandong province Ji'nan City Tianqiao District No. 32 No. 1-2-301 Patentee before: Zhao Yihong |